The aim is to evaluate the efficacy of a quadrivalent vaccine in reducing HPV-associated anogenital diseases among young women.
Conducted a randomized trial, detailed in ClinicalTrials.gov NCT00092521.
Focus on incidence rates of HPV-related anogenital diseases.
Significant reduction in the incidence of HPV-associated anogenital diseases among vaccinated participants.
Abstract
The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women. (ClinicalTrials.gov number, NCT00092521 ClinicalTrials.gov.).